作者
Raphaël Itzykson, Olivier Kosmider, Aline Renneville, Véronique Gelsi-Boyer, Manja Meggendorfer, Margot Morabito, Céline Berthon, Lionel Adès, Pierre Fenaux, Odile Beyne-Rauzy, Norbert Vey, Thorsten Braun, Torsten Haferlach, François Dreyfus, Nicholas CP Cross, Claude Preudhomme, Olivier A Bernard, Michaela Fontenay, William Vainchenker, Susanne Schnittger, Daniel Birnbaum, Nathalie Droin, Eric Solary
发表日期
2013/7/1
期刊
Journal of clinical oncology
卷号
31
期号
19
页码范围
2428-2436
出版商
American Society of Clinical Oncology
简介
Purpose
Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations—including ASXL1—have been associated with poor prognosis in univariable analyses. We developed and validated a prognostic score for overall survival (OS) based on mutational status and standard clinical variables.
Patients and Methods
We genotyped ASXL1 and up to 18 other genes including epigenetic (TET2, EZH2, IDH1, IDH2, DNMT3A), splicing (SF3B1, SRSF2, ZRSF2, U2AF1), transcription (RUNX1, NPM1, TP53), and signaling (NRAS, KRAS, CBL, JAK2, FLT3) regulators in 312 patients with CMML. Genotypes and clinical variables were included in a multivariable Cox model of OS validated by bootstrapping. A scoring system was developed using regression coefficients from this model.
Results
ASXL1 mutations (P < .0001) and, to a lesser …
学术搜索中的文章
R Itzykson, O Kosmider, A Renneville, V Gelsi-Boyer… - Journal of clinical oncology, 2013